GlassScriptPhysician profile
Amanda Barfield
NPI 1972961142
$9,906.70
in general payments reported to CMS, 2019-2025
29 companies · $3,780 in 2025
The $3,780 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $601 · 2022: $1,013 · 2023: $1,986 · 2024: $2,528 · 2025: $3,780.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,055 · Consulting Fee: $1,125 · Education: $113.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,055.11 |
| Consulting Fee | $1,125.00 |
| Education | $113.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,826.34 | 2022-2025 | Tremfya, Simponi Aria, Stelara |
| Abbvie INC. | $1,618.30 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $772.45 | 2021-2025 | Absorica Ld, Winlevi, Ilumya |
| Genzyme Corporation | $743.78 | 2021-2025 | |
| Pfizer INC. | $580.90 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $566.22 | 2021-2025 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $545.10 | 2021-2025 | |
| Lilly USA, LLC | $519.78 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Leo Pharma INC. | $425.46 | 2022-2025 | Adbry, Anzupgo |
| Ucb, INC. | $390.62 | 2021-2025 | Bimzelx |
| Arcutis Biotherapeutics, INC. | $284.92 | 2023-2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $243.53 | 2022-2024 | Sotyktu |
| Galderma Laboratories, L.P. | $238.26 | 2021-2025 | Nemluvio, Aklief |
| Amgen INC. | $220.23 | 2023-2025 | Otezla, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $206.51 | 2022-2025 | Spevigo |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $180.16 | 2021-2024 | Arazlo, Jublia, Targretin |
| Alkermes, INC. | $119.58 | 2023 | Lybalvi |
| Almirall LLC | $89.74 | 2021-2022 | |
| Vyne Pharmaceuticals INC. | $67.79 | 2021 | |
| Incyte Corporation | $49.92 | 2022-2024 | Opzelura |
| Verrica Pharmaceuticals INC. | $44.18 | 2024 | Ycanth |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $35.77 | 2023-2024 | Caplyta |
| Botanix Sb INC | $29.75 | 2025 | Sofdra |
| Biofrontera INC. | $20.88 | 2024 | Xepi, Bf-Rhodoled, Ameluz |
| Dermavant Sciences, INC. | $20.68 | 2024 | Vtama |
| Strata Skin Sciences, INC. | $19.94 | 2024 | Xtrac |
| Biocryst US Sales Co., LLC | $18.97 | 2024 | Orladeyo |
| Blueprint Medicines Corporation | $13.77 | 2023 | |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Barfield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.